|
1
|
McLaughlin CC, Wu XC, Jemal A, Martin HJ,
Roche LM and Chen VW: Incidence of noncutaneous melanomas in the
U.S. Cancer. 103:1000–1007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krantz BA, Dave N, Komatsubara KM, Marr BP
and Carvajal RD: Uveal melanoma: Epidemiology, etiology, and
treatment of primary disease. Clin Ophthalmol. 11:279–289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Damato B: Progress in the management of
patients with uveal melanoma. the 2012 Ashton Lecture. Eye (Lond).
26:1157–1172. 2012. View Article : Google Scholar
|
|
4
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Virgili G, Gatta G, Ciccolallo L,
Capocaccia R, Biggeri A, Crocetti E, Lutz JM and Paci E; EUROCARE
Working Group: Incidence of uveal melanoma in Europe.
Ophthalmology. 114:2309–2315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kivelä T: The epidemiological challenge of
the most frequent eye cancer: Retinoblastoma, an issue of birth and
death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Margo CE, Mulla Z and Billiris K:
Incidence of surgically treated uveal melanoma by race and
ethnicity. Ophthalmology. 105:1087–1090. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shields CL, Kaliki S, Cohen MN, Shields
PW, Furuta M and Shields JA: Prognosis of uveal melanoma based on
race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond).
29:1027–1035. 2015. View Article : Google Scholar
|
|
9
|
Hu DN, Yu GP, McCormick SA, Schneider S
and Finger PT: Population-based incidence of uveal melanoma in
various races and ethnic groups. Am J Ophthalmol.
140:612.e1–612.e8. 2005. View Article : Google Scholar
|
|
10
|
Kaliki S and Shields CL: Uveal melanoma:
Relatively rare but deadly cancer. Eye (Lond). 31:241–257. 2017.
View Article : Google Scholar
|
|
11
|
Singh AD and Topham A: Incidence of uveal
melanoma in the United States: 1973-1997. Ophthalmology.
110:956–961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andreoli MT, Mieler WF and Leiderman YI:
Epidemiological trends in uveal melanoma. Br J Ophthalmol.
99:1550–1553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng CY and Hsu WM: Incidence of eye
cancer in Taiwan: An 18-year review. Eye (Lond). 18:152–158. 2004.
View Article : Google Scholar
|
|
14
|
Liu YM, Li Y, Wei WB, Xu X and Jonas JB:
Clinical characteristics of 582 patients with uveal melanoma in
China. PLoS One. 10:e01445622015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakamoto T, Sakamoto M, Yoshikawa H, Hata
Y, Ishibashi T, Ohnishi Y and Inomata H: Histologic findings and
prognosis of uveal malignant melanoma in Japanese patients. Am J
Ophthalmol. 121:276–283. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh AD, Schoenfield LA, Bastian BC, Aziz
HA, Marino MJ and Biscotti CV: Congenital uveal melanoma? Surv
Ophthalmol. 61:59–64. 2016. View Article : Google Scholar
|
|
17
|
Shields CL, Kaliki S, Arepalli S, Atalay
HT, Manjandavida FP, Pieretti G and Shields JA: Uveal melanoma in
children and teenagers. Saudi J Ophthalmol. 27:197–201. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vajdic CM, Kricker A, Giblin M, McKenzie
J, Aitken J, Giles GG and Armstrong BK: Incidence of ocular
melanoma in Australia from 1990 to 1998. Int J Cancer. 105:117–122.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weis E, Shah CP, Lajous M, Shields JA and
Shields CL: The association between host susceptibility factors and
uveal melanoma: A meta-analysis. Arch Ophthalmol. 124:54–60. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonder JR, Ezell PC, Shields JA and
Augsburger JJ: Ocular melanocytosis: A study to determine the
prevalence rate of ocular melanocytosis. Ophthalmology. 89:950–952.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shields CL, Kaliki S, Livesey M, Walker B,
Garoon R, Bucci M, Feinstein E, Pesch A, Gonzalez C, Lally SE, et
al: Association of ocular and oculodermal melanocytosis with the
rate of uveal melanoma metastasis analysis of 7872 consecutive
eyes. JAMA Ophthalmol. 131:993–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singh AD, De Potter P, Fijal BA, Shields
CL, Shields JA and Elston RC: Lifetime prevalence of uveal melanoma
in white patients with oculo(dermal) melanocytosis. Ophthalmology.
105:195–198. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hammer H, Oláh J and Tóth-Molnár E:
Dysplastic nevi are a risk factor for uveal melanoma. Eur J
Ophthalmol. 6:472–474. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bataille V, Sasieni P, Cuzick J,
Hungerford JL, Swerdlow A and Bishop JA: Risk of ocular melanoma in
relation to cutaneous and iris naevi. Int J Cancer. 60:622–626.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Territo C, Shields CL, Shields JA,
Augsburger JJ and Schroeder RP: Natural course of melanocytic
tumors of the iris. Ophthalmology. 95:1251–1255. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shields CL, Kaliki S, Hutchinson A,
Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K,
Kolbus E, et al: Iris nevus growth into melanoma: Analysis of 1611
consecutive eyes: The ABCDEF guide. Ophthalmology. 120:766–772.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu M and Shields CL: Choroidal nevus in
the United States adult population racial disparities and
associated factors in the national health and nutrition examination
survey. Ophthalmology. 122:2071–2083. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singh AD, Kalyani P and Topham A:
Estimating the risk of malignant transformation of a choroidal
nevus. Ophthalmology. 112:1784–1789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shields CL, Cater J, Shields JA, Singh AD,
Santos MCM and Carvalho C: Combination of clinical factors
predictive of growth of small choroidal melanocytic tumors. Arch
Ophthalmol. 118:360–364. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shields CL, Furuta M, Berman EL, Zahler
JD, Hoberman DM, Dinh DH, Mashayekhi A and Shields JA: Choroidal
nevus transformation into melanoma: Analysis of 2514 consecutive
cases. Arch Ophthalmol. 127:981–987. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carbone M, Yang H, Pass HI, Krausz T,
Testa JR and Gaudino G: BAP1 and cancer. Nat Rev Cancer.
13:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harbour JW, Onken MD, Roberson ED, Duan S,
Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM:
Frequent mutation of BAP1 in metastasizing uveal melanomas.
Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Singh AD, Rennie IG, Seregard S, Giblin M
and McKenzie J: Sunlight exposure and pathogenesis of uveal
melanoma. Surv Ophthalmol. 49:419–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld
N, Sauerwein W and Stang A: Positive interaction between light iris
color and ultraviolet radiation in relation to the risk of uveal
melanoma. A case-control study Ophthalmology. 116:340–348.
2009.
|
|
35
|
Shah CP, Weis E, Lajous M, Shields JA and
Shields CL: Intermittent and chronic ultraviolet light exposure and
uveal melanoma: A meta-analysis. Ophthalmology. 112:1599–1607.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fernandes BF, Marshall JC and Burnier MN
Jr: Blue light exposure and uveal melanoma. Ophthalmology.
113:1062.e1author reply 1062. 2006. View Article : Google Scholar
|
|
37
|
Ge YR, Tian N, Lu Y, Wu Y, Hu QR and Huang
ZP: Occupational cooking and risk of uveal melanoma: A
meta-analysis. Asian Pac J Cancer Prev. 13:4927–4930. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Damato EM and Damato BE: Detection and
time to treatment of uveal melanoma in the United Kingdom: An
evaluation of 2,384 patients. Ophthalmology. 119:1582–1589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shields CL, Kaliki S, Shah SU, Luo W,
Furuta M and Shields JA: Iris melanoma: Features and prognosis in
317 children and adults. J AAPOS. 16:10–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Demirci H, Shields CL, Shields JA, Eagle
RC Jr and Honavar SG: Diffuse iris melanoma: A report of 25 cases.
Ophthalmology. 109:1553–1560. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Demirci H, Shields CL, Shields JA, Eagle
RC Jr and Honavar S: Ring melanoma of the anterior chamber angle: A
report of fourteen cases. Am J Ophthalmol. 132:336–342. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shields CL, Furuta M, Thangappan A, Nagori
S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade
OA, et al: Metastasis of uveal melanoma millimeter-by-millimeter in
8033 consecutive eyes. Arch Ophthalmol. 127:989–998. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shields CL, Manalac J, Das C, Ferguson K
and Shields JA: Choroidal melanoma: Clinical features,
classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol.
25:177–185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Henderson E and Margo CE: Iris melanoma.
Arch Pathol Lab Med. 132:268–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Singh AD and Damato B: Iris melanoma.
Clinical Ophthalmic Oncology: Uveal Tumors. Springer; Berlin: pp.
137–158. 2014, View Article : Google Scholar
|
|
46
|
Shields CL, Manquez ME, Ehya H, Mashayekhi
A, Danzig CJ and Shields JA: Fine-Needle aspiration biopsy of iris
tumors in 100 consecutive cases: Technique and complications.
Ophthalmology. 113:2080–2086. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bianciotto C, Shields CL, Guzman JM,
Romanelli-Gobbi M, Mazzuca D Jr, Green WR and Shields JA:
Assessment of anterior segment tumors with ultrasound biomicroscopy
versus anterior segment optical coherence tomography in 200 cases.
Ophthalmology. 118:1297–1302. 2011.PubMed/NCBI
|
|
48
|
Amaro A, Gangemi R, Piaggio F, Angelini G,
Barisione G, Ferrini S and Pfeffer U: The biology of uveal
melanoma. Cancer Metastasis Rev. 36:109–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ossoinig KC: Standardized echography:
Basic principles, clinical applications, and results. Int
Ophthalmol Clin. 19:127–210. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shields CL, Kaliki S, Rojanaporn D,
Ferenczy SR and Shields JA: Enhanced depth imaging optical
coherence tomography of small choroidal melanoma: Comparison with
choroidal nevus. Arch Ophthalmol. 130:850–856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Augsburger JJ, Golden MI and Shields JA:
Fluorescein angiography of choroidal malignant melanomas with
retinal invasion. Retina. 4:232–241. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shields CL, Shields JA and De Potter P:
Patterns of indocyanine green videoangiography of choroidal
tumours. Br J Ophthalmol. 79:237–245. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shields JA, Mashayekhi A, Ra S and Shields
CL: Pseudomelanomas of the posterior uveal tract: The 2006 Taylor
R. Smith lecture Retina. 25:767–771. 2005. View Article : Google Scholar
|
|
54
|
Shields CL, Dalvin LA, Ancona-Lezama D, Yu
MD, Di Nicola M, Williams BK Jr, Lucio-Alvarez JA, Ang SM, Maloney
S, Welch RJ and Shields JA: Choroidal nevus imaging features in
3,806 cases and risk factors for transformation into Melanoma in
2,355 cases: The 2020 Taylor R. Smith and Victor T Curtin Lecture
Retina. 39:1840–1851. 2019.
|
|
55
|
Accuracy of Diagnosis of Choroidal
Melanomas in the Collaborative Ocular Melanoma Study: COMS Report
No. 1. Arch Ophthalmol. 108:1268–1273. 1990. View Article : Google Scholar
|
|
56
|
Char DH and Miller T: Accuracy of presumed
uveal melanoma diagnosis before alternative therapy. Br J
Ophthalmol. 79:692–696. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shields JA, Shields CL, Ehya H, Eagle RC
Jr and De Potter P: Fine-needle aspiration biopsy of suspected
intraocular tumors. Int Ophthalmol Clin. 33:77–82. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Frizziero L, Midena E, Trainiti S, Londei
D, Bonaldi L, Bini S and Parrozzani R: Uveal melanoma biopsy: A
review. Cancers (Basel). 11:10752019. View Article : Google Scholar
|
|
59
|
Kivelä T, Simpson RE and Grossniklaus HE:
Uveal melanoma. AJCC Cancer Staging Manual. 8th edition. Springer;
New York, NY: 2016
|
|
60
|
Edge S, Byrd D, Compton C, Fritz AG,
Greene F and Trotti A: AJCC Cancer Staging Handbook. The AJCC
Cancer Staging Manual. Springer-Verlag; New York, NY: 2010
|
|
61
|
Hicks C, Foss AJ and Hungerford JL:
Predictive power of screening tests for metastasis in uveal
melanoma. Eye (Lond). 12:945–948. 1998. View Article : Google Scholar
|
|
62
|
Weis E, Salopek TG, McKinnon JG, Larocque
MP, Temple-Oberle C, Cheng T, McWhae J, Sloboda R and Shea-Budgell
M: Management of uveal melanoma: A consensus-based provincial
clinical practice guideline. Curr Oncol. 23:e57–e64. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rietschel P, Panageas KS, Hanlon C, Patel
A, Abramson DH and Chapman PB: Variates of survival in metastatic
uveal melanoma. J Clin Oncol. 23:8076–8080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Diener-West M, Reynolds SM, Agugliaro DJ,
Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi
I, Jampol LM, et al: Development of metastatic disease after
enrollment in the COMS trials for treatment of choroidal melanoma:
Collaborative Ocular Melanoma Study Group Report No. 26. Arch
Ophthalmol. 123:1639–1643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kivelä T: Iris melanomas in children. Arch
Ophthalmol. 119:925–926. 2001.PubMed/NCBI
|
|
66
|
Kaliki S, Shields CL, Mashayekhi A, Ganesh
A, Furuta M and Shields JA: Influence of age on prognosis of young
patients with uveal melanoma: A matched retrospective cohort study.
Eur J Ophthalmol. 23:208–216. 2013. View Article : Google Scholar
|
|
67
|
Shields CL, Shields JA, Materin M,
Gershenbaum E, Singh AD and Smith A: Iris melanoma: Risk factors
for metastasis in 169 consecutive patients. Ophthalmology.
108:172–178. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kujala E, Mäkitie T and Kivelä T: Very
long-term prognosis of patients with malignant uveal melanoma.
Invest Ophthalmol Vis Sci. 44:4651–4659. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shields CL, Kaliki S, Furuta M, Mashayekhi
A and Shields JA: Clinical spectrum and prognosis of uveal melanoma
based on age at presentation in 8,033 cases. Retina. 32:1363–1372.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zloto O, Pe'er J and Frenkel S: Gender
differences in clinical presentation and prognosis of uveal
melanoma. Invest Ophthalmol Vis Sci. 54:652–656. 2013. View Article : Google Scholar
|
|
71
|
Hawkins BS; Collaborative Ocular Melanoma
Study Group: The Collaborative Ocular Melanoma Study (COMS)
randomized trial of pre-enucleation radiation of large choroidal
melanoma: IV. Ten-year mortality findings and prognostic factors.
COMS report number 24. Am J Ophthalmol. 138:936–951. 2004.
View Article : Google Scholar
|
|
72
|
Collaborative Ocular Melanoma Study Group:
The COMS randomized trial of iodine 125 brachytherapy for choroidal
melanoma: V. Twelve-year mortality rates and prognostic factors:
COMS report no. 28. Arch Ophthalmol. 124:1684–1693. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Diener-West M, Hawkins BS, Markowitz JA
and Schachat AP: A review of mortality from choroidal melanoma: II.
A Meta-Analysis of 5-Year mortality rates following enucleation,
1966 through 1988. Arch Ophthalmol. 110:245–250. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Shields CL, Kaliki S, Furuta M, Fulco E,
Alarcon C and Shields JA: American Joint Committee on cancer
classification of posterior uveal melanoma (tumor size category)
predicts prognosis in 7731 patients. Ophthalmology. 120:2066–2071.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li W, Gragoudas ES and Egan KM: Metastatic
melanoma death rates by anatomic site after proton beam irradiation
for uveal melanoma. Arch Ophthalmol. 118:1066–1070. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kaliki S, Shields CL and Shields JA: Uveal
melanoma: Estimating prognosis. Indian J Ophthalmol. 63:93–102.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Pach JM, Robertson DM, Taney BS, Martin
JA, Campbell RJ and O'Brien PC: Prognostic factors in choroidal and
ciliary body melanomas with extrascleral extension. Am J
Ophthalmol. 101:325–331. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
McLean MJ, Foster WD and Zimmerman LE:
Prognostic factors in small malignant melanomas of choroid and
ciliary body. Arch Ophthalmol. 95:48–58. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Al-Jamal RT, Mäkitie T and Kivelä T:
Nucleolar diameter and microvascular factors as independent
predictors of mortality from malignant melanoma of the choroid and
ciliary body. Invest Ophthalmol Vis Sci. 44:2381–2389. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Prescher G, Bornfeld N, Hirche H,
Horsthemke B, Jöckel KH and Becher R: Prognostic implications of
monosomy 3 in uveal melanoma. Lancet. 347:1222–1225. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kilic E, Naus NC, Van Gils W, Klaver CC,
van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo
HB, et al: Concurrent loss of chromosome arm 1p and chromosome 3
predicts a decreased disease-free survival in uveal melanoma
patients. Invest Ophthalmol Vis Sci. 46:2253–2257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Scholes AG, Damato BE, Nunn J, Hiscott P,
Grierson I and Field JK: Monosomy 3 in uveal melanoma: Correlation
with clinical and histologic predictors of survival. Invest
Ophthalmol Vis Sci. 44:1008–1011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ehlers JP, Worley L, Onken MD and Harbour
JW: Integrative genomic analysis of aneuploidy in uveal melanoma.
Clin Cancer Res. 14:115–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Aalto Y, Eriksson L, Seregard S, Larsson O
and Knuutila S: Concomitant loss of chromosome 3 and whole arm
losses and gains of chromosome 1, 6, or 8 in metastasizing primary
uveal melanoma. Invest Ophthalmol Vis Sci. 42:313–317.
2001.PubMed/NCBI
|
|
85
|
Onken MD, Worley LA, Ehlers JP and Harbour
JW: Gene expression profiling in uveal melanoma reveals two
molecular classes and predicts metastatic death. Cancer Res.
64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Onken MD, Worley LA, Char DH, Augsburger
JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein
DS, Finger PT, et al: Collaborative ocular oncology group report
number 1: Prospective validation of a multi-gene prognostic assay
in uveal melanoma. Ophthalmology. 119:1596–1603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Harbour JW and Chen R: The DecisionDx-UM
gene expression profile test provides risk stratification and
individualized patient care in uveal melanoma. PLoS Curr. April
9–2013.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Field MG and Harbour JW: Recent
developments in prognostic and predictive testing in uveal
melanoma. Curr Opin Ophthalmol. 25:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Eskelin S, Pyrhönen S, Summanen P,
Hahka-Kemppinen M and Kivelä T: Tumor doubling times in metastatic
malignant melanoma of the uvea: Tumor progression before and after
treatment. Ophthalmology. 107:1443–1449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Natarajan S: Ocular oncology-a
multidisciplinary specialty. Indian J Ophthalmol. 63:912015.
View Article : Google Scholar
|
|
91
|
Rantala ES, Hernberg M and Kivelä TT:
Overall survival after treatment for metastatic uveal melanoma: A
systematic review and meta-analysis. Melanoma Res. 29:561–568.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Brewington BY, Shao YF, Davidorf FH and
Cebulla CM: Brachytherapy for patients with uveal melanoma:
Historical perspectives and future treatment directions. Clin
Ophthalmol. 12:925–934. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Rospond-Kubiak I and Damato B: The
surgical approach to the management of anterior uveal melanomas.
Eye (Lond). 28:741–747. 2014. View Article : Google Scholar
|
|
94
|
Jonas JB, Groh MJ, Rummelt V and Naumann
GOH: Rhegmatogenous retinal detachment after block excision of
epithelial implantation cysts and tumors of the anterior uvea.
Ophthalmology. 106:1942–1946. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Nelson F, Stine GH and Danielson RW:
Malignant melanoma of iris and ciliary body. Am J Ophthalmol.
29:13101946.PubMed/NCBI
|
|
96
|
Damato B, Kacperek A, Chopra M, Sheen MA,
Campbell IR and Errington RD: Proton beam radiotherapy of iris
melanoma. Int J Radiat Oncol Biol Phys. 63:109–115. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Finger PT: Plaque radiation therapy for
malignant melanoma of the iris and ciliary body. Am J Ophthalmol.
132:328–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Shields CL, Naseripour M, Shields JA,
Freire J and Cater J: Custom-designed plaque radiotherapy for
nonresectable iris melanoma in 38 patients: Tumor control and
ocular complications. Am J Ophthalmol. 135:648–656. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lloyd JP and Ellis F: Melanoma of iris
treated by radiation therapy. Br J Ophthalmol. 39:507–509. 1955.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Konstantinidis L, Roberts D, Errington RD,
Kacperek A and Damato B: Whole anterior segment proton beam
radiotherapy for diffuse iris melanoma. Br J Ophthalmol.
97:471–474. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Finger PT, Tomar AS and Chin KJ:
Palladium-103 plaque therapy for multifocal iris melanoma:
Radiation of the entire anterior segment of the eye. Eur J
Ophthalmol. 1120672120914235:2020.Epub ahead of print.
|
|
102
|
Rundle P, Singh AD and Rennie I: Proton
beam therapy for iris melanoma: A review of 15 cases. Eye (Lond).
21:79–82. 2007. View Article : Google Scholar
|
|
103
|
Rahmi A, Mammar H, Thariat J, Angellier G,
Herault J, Chauvel P, Kodjikian L, Denis P and Grange JD: Proton
beam therapy for presumed and confirmed iris melanomas: A review of
36 cases. Graefes Arch Clin Exp Ophthalmol. 252:1515–1521. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Shields CL, Shah SU, Bianciotto CG, Emrich
J, Komarnicky L and Shields JA: Iris melanoma management with
iodine-125 plaque radiotherapy in 144 patients: Impact of
melanoma-related glaucoma on outcomes. Ophthalmology. 120:55–61.
2013. View Article : Google Scholar
|
|
105
|
American Brachytherapy Society-Ophthalmic
Oncology Task Force. Electronic address: paulfinger@eyecancer.com;
ABS-OOTF Committee: The American Brachytherapy Society consensus
guidelines for plaque brachytherapy of uveal melanoma and
retinoblastoma. Brachytherapy. 13:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dogrusöz M, Jager MJ and Damato B: Uveal
melanoma treatment and prognostication. Asia Pac J Ophthalmol
(Phila). 6:186–196. 2017.
|
|
107
|
Honavar SG: Is collaborative ocular
melanoma study (COMS) still relevant? Indian J Ophthalmol.
66:1385–1387. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Damato B: Legacy of the collaborative
ocular melanoma study. Arch Ophthalmol. 125:966–968. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zimmerman LE, McLean IW and Foster WD:
Does enucleation of the eye containing a malignant melanoma prevent
or accelerate the dissemination of tumour cells? Br J Ophthalmol.
62:420–425. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hawkins BS: Collaborative Ocular Melanoma
Study randomized trial of I-125 brachytherapy. Clin Trials.
8:661–673. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Finger PT, Chin KJ and Duvall G;
Palladium-103 for Choroidal Melanoma Study Group: Palladium-103
ophthalmic plaque radiation therapy for choroidal melanoma: 400
treated patients. Ophthalmology. 116:790–6. 796.e12009. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Verma V and Mehta MP: Clinical outcomes of
proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol).
28:e17–e27. 2016. View Article : Google Scholar
|
|
113
|
Gragoudas ES: Proton beam irradiation of
uveal melanomas: The first 30 years. The weisenfeld lecture. Invest
Ophthalmol Vis Sci. 47:4666–4673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yang J, Manson DK, Marr BP and Carvajal
RD: Treatment of uveal melanoma: Where are we now? Ther Adv Med
Oncol. 10:17588340187571752018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Damato B, Kacperek A, Errington D and
Heimann H: Proton beam radiotherapy of uveal melanoma. Saudi J
Ophthalmol. 27:151–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Papakostas TD, Lane AM, Morrison M,
Gragoudas ES and Kim IK: Long-term outcomes after proton beam
irradiation in patients with large choroidal melanomas. JAMA
Ophthalmol. 135:1191–1196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu
S, Kircher K, Georgopoulos M, Georg D, Zehetmayer M and Poetter R:
Local tumor control, visual acuity, and survival after
hypofractionated stereotactic photon radiotherapy of choroidal
melanoma in 212 patients treated between 1997-2007. Int J Radiat
Oncol Biol Phys. 81:199–205. 2011. View Article : Google Scholar
|
|
118
|
Gragoudas ES, Li W, Lane AM, Munzenrider J
and Egan KM: Risk factors for radiation maculopathy and
papillopathy after intraocular irradiation. Ophthalmology.
106:1571–1578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Shields JA and Shields CL: Management of
posterior uveal melanoma: Past, present, and Future: The 2014
Charles L. schepens lecture. Ophthalmology. 122:414–428. 2015.
View Article : Google Scholar
|
|
120
|
Damato B and Lecuona K: Conservation of
eyes with choroidal melanoma by a multimodality approach to
treatment: An audit of 1632 patients. Ophthalmology. 111:977–983.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Shields JA, Shields CL, Shah P and
Sivalingam V: Partial lamellar sclerouvectomy for ciliary body and
choroidal tumors. Ophthalmology. 98:971–983. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Peyman GA and Gremillion CM: Eye wall
resection in the management of uveal neoplasms. Jpn J Ophthalmol.
33:458–471. 1989.PubMed/NCBI
|
|
123
|
Damato BE, Paul J and Foulds WS:
Predictive factors of visual outcome after local resection of
choroidal melanoma. Br J Ophthalmol. 77:616–623. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Foulds WS, Damato BE and Burton RL: Local
resection versus enucleation in the management of choroidal
melanoma. Eye (Lond). 1(Pt 6): 676–679. 1987. View Article : Google Scholar
|
|
125
|
Damato BE, Paul J and Foulds WS: Risk
factors for residual and recurrent uveal melanoma after
trans-scleral local resection. Br J Ophthalmol. 80:102–108. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Caminal JM, Padrón-Pérez N, Arias L,
Masuet-Aumatell C, Gutiérrez C, Piulats JM, Pera J, Català J, Rubio
MJ and Arruga J: Transscleral resection without hypotensive
anaesthesia vs iodine-125 plaque brachytherapy in the treatment of
choroidal melanoma. Eye (Lond). 30:833–842. 2016. View Article : Google Scholar
|
|
127
|
Konstantinidis L, Groenewald C, Coupland
SE and Damato B: Long-term outcome of primary endoresection of
choroidal melanoma. Br J Ophthalmol. 98:82–85. 2014. View Article : Google Scholar
|
|
128
|
Biewald E, Lautner H, Gök M, Horstmann GA,
Sauerwein W, Flühs D and Bornfeld N: Endoresection of large uveal
melanomas: Clinical results in a consecutive series of 200 cases.
Br J Ophthalmol. 101:204–208. 2017. View Article : Google Scholar
|
|
129
|
Süsskind D, Dürr C, Paulsen F, Kaulich T
and Bartz-Schmidt KU: Endoresection with adjuvant ruthenium
brachytherapy for selected uveal melanoma patients-the Tuebingen
experience. Acta Ophthalmol. 95:e727–e733. 2017. View Article : Google Scholar
|
|
130
|
Mashayekhi A, Shields CL, Rishi P, Atalay
HT, Pellegrini M, McLaughlin JP, Patrick KA, Morton SJ, Remmer MH,
Parendo A, et al: Primary transpupillary thermotherapy for
choroidal melanoma in 391 cases: Importance of risk factors in
tumor control. Ophthalmology. 122:600–609. 2015. View Article : Google Scholar
|
|
131
|
Shields CL, Shields JA, Perez N, Singh AD
and Cater J: Primary transpupillary thermotherapy for small
choroidal melanoma in 256 consecutive cases: Outcomes and
limitations. Ophthalmology. 109:225–234. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Harbour JW, Meredith TA, Thompson PA and
Gordon ME: Transpupillary thermotherapy versus plaque radiotherapy
for suspected choroidal melanomas. Ophthalmology. 110:2207–2214;
discussion 2215. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Yarovoy AA, Magaramov DA and Bulgakova ES:
The comparison of ruthenium brachytherapy and simultaneous
transpupillary thermotherapy of choroidal melanoma with
brachytherapy alone. Brachytherapy. 11:224–229. 2012. View Article : Google Scholar
|
|
134
|
Marinkovic M, Horeweg N, Fiocco M, Peters
FP, Sommers LW, Laman MS, Bleeker JC, Ketelaars M, Luyten GP and
Creutzberg CL: Ruthenium-106 brachytherapy for choroidal melanoma
without transpupillary thermotherapy: Similar efficacy with
improved visual outcome. Eur J Cancer. 68:106–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Desjardins L, Lumbroso-Le Rouic L,
Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, Estève M,
Plancher C and Asselain B: Combined proton beam radiotherapy and
transpupillary thermotherapy for large uveal melanomas: A
randomized study of 151 patients. Ophthalmic Res. 38:255–260. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Bellerive C, Aziz HA, Bena J, Wilkinson A,
Suh JH, Plesec T and Singh AD: Local failure after episcleral
brachytherapy for posterior uveal melanoma: Patterns, risk factors,
and management. Am J Ophthalmol. 177:9–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Cerman E and Çekiç O: Clinical use of
photodynamic therapy in ocular tumors. Surv Ophthalmol. 60:557–574.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Turkoglu EB, Pointdujour-Lim R, Mashayekhi
A and Shields CL: Photodynamic therapy as primary treatment for
small choroidal melanoma. Retina. 39:1319–1325. 2019. View Article : Google Scholar
|
|
139
|
Liggett PE, Lavaque AJ, Chaudhry NA,
Jablon EP and Quiroz-Mercado H: Preliminary results of combined
simultaneous transpupillary thermotherapy and ICG-based
photodynamic therapy for choroidal melanoma. Ophthalmic Surg Lasers
Imaging. 36:463–470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Rose AM, Cowen S, Jayasena CN, Verity DH
and Rose GE: Presentation, treatment, and prognosis of secondary
melanoma within the orbit. Front Oncol. 7:1252017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Finger PT and Chin KJ: Antivascular
endothelial growth factor bevacizumab for radiation optic
neuropathy: Secondary to plaque radiotherapy. Int J Radiat Oncol
Biol Phys. 82:789–798. 2012. View Article : Google Scholar
|
|
142
|
Nagendran ST and Finger PT: Anti-VEGF
intravitreal bevacizumab for radiation-associated neovascular
glaucoma. Ophthalmic Surg Lasers Imaging Retin. 46:201–207. 2015.
View Article : Google Scholar
|
|
143
|
Fallico M, Chronopoulos A, Schutz JS and
Reibaldi M: Treatment of radiation maculopathy and
radiation-induced macular edema: A systematic review. Surv
Ophthalmol. Sep 10–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Fallico M, Reibaldi M, Avitabile T, Longo
A, Bonfiglio V, Chronopoulos A, Caltabiano R, Spatola C and Russo
A: Intravitreal aflibercept for the treatment of radiation-induced
macular edema after ruthenium 106 plaque radiotherapy for choroidal
melanoma. Graefes Arch Clin Exp Ophthalmol. 257:1547–1554. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Gomez D, Wetherill C, Cheong J, Jones L,
Marshall E, Damato B, Coupland SE, Ghaneh P, Poston GJ, Malik HZ
and Fenwick SW: The Liverpool uveal melanoma liver metastases
pathway: Outcome following liver resection. J Surg Oncol.
109:542–547. 2014. View Article : Google Scholar
|
|
146
|
Davanzo JM, Binkley EM, Bena JF and Singh
AD: Risk-stratified systemic surveillance in uveal melanoma. Br J
Ophthalmol. 103:1868–1871. 2019.PubMed/NCBI
|
|
147
|
Carvajal RD, Schwartz GK, Tezel T, Marr B,
Francis JH and Nathan PD: Metastatic disease from uveal melanoma:
Treatment options and future prospects. Br J Ophthalmol. 101:38–44.
2017. View Article : Google Scholar :
|
|
148
|
Ralli M, Botticelli A, Visconti IC,
Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M and
Greco A: Immunotherapy in the treatment of metastatic melanoma:
Current knowledge and future directions. J Immunol Res.
2020:92356382020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Basile MS, Mazzon E, Russo A, Mammana S,
Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti
F, et al: Differential modulation and prognostic values of
immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Basile MS, Mazzon E, Fagone P, Longo A,
Russo A, Fallico M, Bonfiglio V, Nicoletti F, Avitabile T and
Reibaldi M: Immunobiology of uveal melanoma: State of the art and
therapeutic targets. Front Oncol. 9:11452019. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Schadendorf D, Ascierto PA, Haanen JBAG,
Espinosa E, Demidov LV, Garbe C, Lorigan P, Gogas H, Hoeller C,
Guren TK, et al: Efficacy and safety of nivolumab (NIVO) in
patients with advanced melanoma (MEL) and poor prognostic factors
who progressed on or after ipilimumab (IPI): Results from a phase
II study (CheckMate 172). J Clin Oncol. 35(Suppl 15): S95242017.
View Article : Google Scholar
|
|
152
|
Najjar YG, Navrazhina K, Ding F, Bhatia R,
Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, et al:
Ipilimumab plus nivolumab for patients with metastatic uveal
melanoma: A multicenter, retrospective study. J Immunother Cancer.
8:e0003312020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Cruz F, Rubin BP, Wilson D, Town A,
Schroeder A, Haley A, Bainbridge T, Heinrich MC and Corless CL:
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res.
63:5761–5766. 2003.PubMed/NCBI
|
|
154
|
Carvajal RD, Sosman JA, Quevedo JF, Milhem
MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J,
Lawson DH, et al: Effect of selumetinib vs chemotherapy on
progression-free survival in uveal melanoma: A randomized clinical
trial. JAMA. 311:2397–2405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Carvajal RD, Piperno-Neumann S, Kapiteijn
E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V,
Chmielowski B, et al: Selumetinib in combination with dacarbazine
in patients with metastatic uveal melanoma: A phase III,
multicenter, randomized trial (SUMIT). J Clin Oncol. 36:1232–1239.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Falchook GS, Lewis KD, Infante JR, Gordon
MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT,
et al: Activity of the oral MEK inhibitor trametinib in patients
with advanced melanoma: A phase 1 dose-escalation trial. Lancet
Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Shoushtari AN, Kudchadkar RR, Panageas K,
Murthy RK, Jung M, Shah R, O'Donnell B, Khawaja TT, Shames Y,
Prempeh-Keteku NA, et al: A randomized phase 2 study of trametinib
with or without GSK2141795 in patients with advanced uveal
melanoma. J Clin Oncol. 34(Suppl 15): S95112016. View Article : Google Scholar
|
|
158
|
Piperno-Neumann S, Kapiteijn E, Larkin JM,
Carvajal RD, Luke JJ, Roozen HS, Zoubir M, Yang L, Choudhury S,
Yerramilli-Rao P, et al: Phase I dose-escalation study of the
protein kinase C (PKC) inhibitor AEB071 in patients with metastatic
uveal melanoma. J Clin Oncol. 32(Suppl 15): 90302014. View Article : Google Scholar
|
|
159
|
Mahipal A, Tijani L, Chan K, Laudadio M,
Mastrangelo MJ and Sato T: A pilot study of sunitinib malate in
patients with metastatic uveal melanoma. Melanoma Res. 22:440–446.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Valsecchi ME, Orloff M, Sato R, Chervoneva
I, Shields CL, Shields JA, Mastrangelo MJ and Sato T: Adjuvant
sunitinib in high-risk patients with uveal melanoma: Comparison
with institutional controls. Ophthalmology. 125:210–217. 2018.
View Article : Google Scholar
|
|
161
|
Luke JJ, Olson DJ, Allred JB, Strand CA,
Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, et al:
Randomized Phase II trial and tumor mutational spectrum analysis
from cabozantinib versus chemotherapy in metastatic uveal melanoma
(Alliance A091201). Clin Cancer Res. 26:804–811. 2020. View Article : Google Scholar :
|
|
162
|
Scheulen ME, Kaempgen E, Keilholz U,
Heinzerling L, Ochsenreither S, Abendroth A, Hilger RA, Grubert M,
Wetter A, Guberina N, et al: STREAM: A randomized discontinuation,
blinded, placebo-controlled phase II study of sorafenib (S)
treatment of chemonaïve patients (pts) with metastatic uveal
melanoma (MUM). J Clin Oncol. 35:9511. 2017. View Article : Google Scholar
|
|
163
|
Khoja L, Atenafu EG, Suciu S, Leyvraz S,
Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann
S, et al: Meta-analysis in metastatic uveal melanoma to determine
progression free and overall survival benchmarks: An international
rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol.
30:1370–1380. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Rowcroft A, Loveday BPT, Thomson BNJ,
Banting S and Knowles B: Systematic review of liver directed
therapy for uveal melanoma hepatic metastases. HPB (Oxford).
22:497–505. 2020. View Article : Google Scholar
|
|
165
|
Leyvraz S, Piperno-Neumann S, Suciu S,
Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary
T, Negrier S, et al: Hepatic intra-arterial versus intravenous
fotemustine in patients with liver metastases from uveal melanoma
(EORTC 18021): A multicentric randomized trial. Ann Oncol.
25:742–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Vogl TJ, Koch SA, Lotz G, Gebauer B,
Willinek W, Engelke C, Brüning R, Zeile M, Wacker F, Vogel A, et
al: Percutaneous isolated hepatic perfusion as a treatment for
isolated hepatic metastases of uveal melanoma: Patient outcome and
safety in a multi-centre study. Cardiovasc Intervent Radiol.
40:864–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Gonsalves CF, Eschelman DJ, Adamo RD, Anne
PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I and Sato T: A
prospective Phase II trial of radioembolization for treatment of
uveal melanoma hepatic metastasis. Radiology. 293:223–231. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Sharma A, Stei MM, Fröhlich H, Holz FG,
Loeffler KU and Herwig-Carl MC: Genetic and epigenetic insights
into uveal melanoma. Clin Genet. 93:952–961. 2018. View Article : Google Scholar
|
|
169
|
Lobo J, Pinto C, Freitas M, Pinheiro M,
Vizcaino R, Oliva E, Teixeira MR, Jerónimo C and Bartosch C:
Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss
in a patient with germline MLH1 mutated Lynch syndrome: Consequence
or coincidence? Virchows Arch. 470:347–352. 2017. View Article : Google Scholar
|
|
170
|
Rai K, Pilarski R, Cebulla CM and
Abdel-Rahman MH: Comprehensive review of BAP1 tumor predisposition
syndrome with report of two new cases. Clin Genet. 89:285–294.
2016. View Article : Google Scholar
|
|
171
|
Larribère L and Utikal J: Update on GNA
alterations in cancer: Implications for uveal melanoma treatment.
Cancers (Basel). 12:15242020. View Article : Google Scholar
|
|
172
|
Leonardi GC, Falzone L, Salemi R, Zanghì
A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous
melanoma: From pathogenesis to therapy (Review). Int J Oncol.
52:1071–1080. 2018.PubMed/NCBI
|
|
173
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green
G, Bouvier N, et al: Mutations in GNA11 in Uveal Melanoma. N Engl J
Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Onken MD, Worley LA, Long MD, Duan S,
Council ML, Bowcock AM and Harbour JW: Oncogenic mutations in GNAQ
occur early in uveal melanoma. Invest Ophthalmol Vis Sci.
49:5230–5234. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Landreville S, Agapova OA, Matatall KA,
Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone
deacetylase inhibitors induce growth arrest and differentiation in
uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar :
|
|
176
|
Abdel-Rahman MH, Pilarski R, Cebulla CM,
Massengill JB, Christopher BN, Boru G, Hovland P and Davidorf FH:
Germline BAP1 mutation predisposes to uveal melanoma, lung
adenocarcinoma, meningioma, and other cancers. J Med Genet.
48:856–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Levinzon L, Madigan M, Nguyen V, Hasic E,
Conway M and Cherepanoff S: Tumour expression of histone
deacetylases in uveal melanoma. Ocul Oncol Pathol. 5:153–161. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Fabbri M and Calin GA: Epigenetics and
miRNAs in human cancer. Adv Genet. 70:87–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Cedar H and Bergman Y: Linking DNA
methylation and histone modification: Patterns and paradigms. Nat
Rev Genet. 10:295–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Zhang W and Xu J: DNA methyltransferases
and their roles in tumorigenesis. Biomark Res. 5:12017. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Li S, Zhang J, Huang S and He X:
Genome-wide analysis reveals that exon methylation facilitates its
selective usage in the human transcriptome. Brief Bioinform.
19:754–764. 2018. View Article : Google Scholar
|
|
182
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Falzone L, Salemi R, Travali S, Scalisi A,
McCubrey JA, Candido S and Libra M: MMP-9 overexpression is
associated with intragenic hypermethylation of MMP9 gene in
melanoma. Aging (Albany NY). 8:933–944. 2016. View Article : Google Scholar
|
|
184
|
Zhao Y, Sun H and Wang H: Long noncoding
RNAs in DNA methylation: New players stepping into the old game.
Cell Biosci. 6:452016. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Shayevitch R, Askayo D, Keydar I and Ast
G: The importance of DNA methylation of exons on alternative
splicing. RNA. 24:1351–1362. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Ehrlich M and Lacey M: DNA methylation and
differentiation: Silencing, upregulation and modulation of gene
expression. Epigenomics. 5:553–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Field MG, Durante MA, Decatur CL, Tarlan
B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S
and Harbour JW: Epigenetic reprogramming and aberrant expression of
PRAME are associated with increased metastatic risk in Class 1 and
2 uveal melanomas. Oncotarget. 7:59209–59219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Venza M, Visalli M, Catalano T, Beninati
C, Teti D and Venza I: DSS1 promoter hypomethylation and
overexpression predict poor prognosis in melanoma and squamous cell
carcinoma patients. Hum Pathol. 60:137–146. 2017. View Article : Google Scholar
|
|
189
|
Merhavi E, Cohen Y, Avraham BC, Frenkel S,
Chowers I, Pe'er J and Goldenberg-Cohen N: Promoter methylation
status of multiple genes in uveal melanoma. Invest Ophthalmol Vis
Sci. 48:4403–4406. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Moulin AP, Clément G, Bosman FT, Zografos
L and Benhattar J: Methylation of CpG island promoters in uveal
melanoma. Br J Ophthalmol. 92:281–285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Maat W, Van Der Velden PA, Out-Luiting C,
Plug M, Dirks-Mulder A, Jager MJ and Gruis NA: Epigenetic
inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis
Sci. 48:486–490. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Maat W, Beiboer SH, Jager MJ, Luyten GP,
Gruis NA and Van Der Velden PA: Epigenetic regulation identifies
RASEF as a tumor-suppressor gene in uveal melanoma. Invest
Ophthalmol Vis Sci. 49:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Van der Velden PA, Zuidervaart W, Hurks
MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen CP,
Willemze R, Jager MJ and Gruis NA: Expression profiling reveals
that methylation of TIMP3 is involved in uveal melanoma
development. Int J Cancer. 106:472–479. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Neumann LC, Weinhäusel A, Thomas S,
Horsthemke B, Lohmann DR and Zeschnigk M: EFS shows biallelic
methylation in uveal melanoma with poor prognosis as well as
tissue-specific methylation. BMC Cancer. 11:3802011. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Venza M, Visalli M, Catalano T, Fortunato
C, Oteri R, Teti D and Venza I: Impact of DNA methyltransferases on
the epigenetic regulation of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) receptor expression in malignant
melanoma. Biochem Biophys Res Commun. 441:743–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Field MG, Kuznetsov JN, Bussies PL, Cai
LZ, Alawa KA, Decatur CL, Kurtenbach S and Harbour JW: BAP1 loss is
associated with DNA methylomic repatterning in highly aggressive
class 2 uveal melanomas. Clin Cancer Res. 25:5663–5673. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Falzone L, Romano GL, Salemi R, Bucolo C,
Tomasello B, Lupo G, Anfuso CD, Spandidos DA, Libra M and Candido
S: Prognostic significance of deregulated microRNAs in uveal
melanomas. Mol Med Rep. 19:2599–2610. 2019.PubMed/NCBI
|
|
198
|
Beyer S, Fleming J, Meng W, Singh R, Haque
SJ and Chakravarti A: The Role of miRNAs in angiogenesis, invasion
and metabolism and their therapeutic implications in gliomas.
Cancers (Basel). 9:852017. View Article : Google Scholar
|
|
199
|
Napoli S, Scuderi C, Gattuso G, Bella VD,
Candido S, Basile MS, Libra M and Falzone L: Functional roles of
matrix metalloproteinases and their inhibitors in melanoma. Cells.
9:11512020. View Article : Google Scholar :
|
|
200
|
Filetti V, Falzone L, Rapisarda V,
Caltabiano R, Eleonora Graziano AC, Ledda C and Loreto C:
Modulation of microRNA expression levels after naturally occurring
asbestiform fibers exposure as a diagnostic biomarker of
mesothelial neoplastic transformation. Ecotoxicol Environ Saf.
198:1106402020. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Falzone L, Grimaldi M, Celentano E,
Augustin LSA and Libra M: Identification of modulated MicroRNAs
associated with breast cancer, diet, and physical activity. Cancers
(Basel). 12:25552020. View Article : Google Scholar
|
|
202
|
Polo A, Crispo A, Cerino P, Falzone L,
Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon
A and Costantini S: Environment and bladder cancer: Molecular
analysis by interaction networks. Oncotarget. 8:65240–65252. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Crimi S, Falzone L, Gattuso G, Grillo CM,
Candido S, Bianchi A and Libra M: Droplet Digital PCR analysis of
liquid biopsy samples unveils the diagnostic role of
hsa-miR-133a-3p and hsa-miR-375-3p in oral cancer. Biology (Basel).
9:3792020.
|
|
204
|
Venza M, Dell'Aversana C, Visalli M,
Altucci L, Teti D and Venza I: Identification of microRNA
expression patterns in cutaneous and uveal melanoma cell lines.
Tumori. 100:e4–e7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Radhakrishnan A, Badhrinarayanan N, Biswas
J and Krishnakumar S: Analysis of chromosomal aberration (1, 3, and
8) and association of microRNAs in uveal melanoma. Mol Vis.
15:2146–2154. 2009.PubMed/NCBI
|
|
206
|
Larsen AC, Holst L, Kaczkowski B, Andersen
MT, Manfé V, Siersma VD, Kolko M, Kiilgaard JF, Winther O, Prause
JU, et al: MicroRNA expression analysis and Multiplex
ligation-dependent probe amplification in metastatic and
non-metastatic uveal melanoma. Acta Ophthalmol. 92:541–549. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Worley LA, Long MD, Onken MD and Harbour
JW: Micro-RNAs associated with metastasis in uveal melanoma
identified by multiplexed microarray profiling. Melanoma Res.
18:184–190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Chen X, Wang J, Shen H, Lu J, Li C, Hu DN,
Dong XD, Yan D and Tu L: Epigenetics, microRNAs, and
carcinogenesis: Functional role of microRNA-137 in uveal melanoma.
Invest Ophthalmol Vis Sci. 52:1193–1199. 2011. View Article : Google Scholar
|
|
209
|
Li Y, Huang Q, Shi X, Jin X, Shen L, Xu X
and Wei W: MicroRNA 145 may play an important role in uveal
melanoma cell growth by potentially targeting insulin receptor
substrate-1. Chin Med J (Engl). 127:1410–1416. 2014.
|
|
210
|
Eedunuri VK, Rajapakshe K, Fiskus W, Geng
C, Chew SA, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, et al:
miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and
SRC3 and inhibits cell proliferation. Mol Endocrinol. 29:1170–1183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Venza M, Visalli M, Beninati C, Benfatto
S, Teti D and Venza I: miR-92a-3p and MYCBP2 are involved in
MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma
cells. Int Immunopharmacol. 40:235–243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Sun L, Bian G, Meng Z, Dang G, Shi D and
Mi S: MiR-144 inhibits uveal melanoma cell proliferation and
invasion by regulating c-Met expression. PLoS One. 10:e01244282015.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Zhang L, He X, Li F, Pan H, Huang X, Wen
X, Zhang H, Li B, Ge S, Xu X, et al: The miR-181 family promotes
cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor
in uveal melanoma. J Exp Clin Cancer Res. 37:152018. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Wang Y, Luo Y, Guan W and Zhao H: Role of
mir-23a/zeb1 negative feedback loop in regulating
epithelial-mesenchymal transition and tumorigenicity of intraocular
tumors. Oncol Lett. 16:2462–2470. 2018.PubMed/NCBI
|
|
215
|
Wang YC, Yang X, Wei WB and Xu XL: Role of
microRNA-21 in uveal melanoma cell invasion and metastasis by
regulating p53 and its downstream protein. Int J Ophthalmol.
11:1258–1268. 2018.PubMed/NCBI
|
|
216
|
Li J, Liu X, Li C and Wang W: miR-224-5p
inhibits proliferation, migration, and invasion by targeting
PIK3R3/AKT3 in uveal melanoma. J Cell Biochem. 120:12412–12421.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Sun L, Wang Q, Gao X, Shi D, Mi S and Han
Q: MicroRNA-454 functions as an oncogene by regulating PTEN in
uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Ling JW, Lu PR, Zhang YB, Jiang S and
Zhang ZC: miR-367 promotes uveal melanoma cell proliferation and
migration by regulating PTEN. Genet Mol Res. 16:2017. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Peng J, Liu H and Liu C: MiR-155 promotes
uveal melanoma cell proliferation and invasion by regulating NDFIP1
expression. Technol Cancer Res Treat. 16:1160–1167. 2017.
View Article : Google Scholar
|
|
220
|
Wang X, Hu Y, Cui J, Zhou Y and Chen L:
Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts
tumor-suppressing effects in choroidal malignant melanoma. Mol Cell
Biochem. 445:25–33. 2018. View Article : Google Scholar
|
|
221
|
Zhou J, Jiang J, Wang S and Xia X:
Oncogenic role of microRNA-20a in human uveal melanoma. Mol Med
Rep. 14:1560–1566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Yang C and Wei W: The miRNA expression
profile of the uveal melanoma. Sci China Life Sci. 54:351–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Achberger S, Aldrich W, Tubbs R, Crabb JW,
Singh AD and Triozzi PL: Circulating immune cell and microRNA in
patients with uveal melanoma developing metastatic disease. Mol
Immunol. 58:182–186. 2014. View Article : Google Scholar :
|
|
224
|
Venza I, Visalli M, Beninati C, Benfatto
S, Teti D and Venza M: IL-10Rα expression is post-transcriptionally
regulated by MIR-15a, MIR-185, and MIR-211 in melanoma. BMC Med
Genomics. 8:812015. View Article : Google Scholar
|
|
225
|
Sun Q, Cong R, Yan H, Gu H, Zeng Y, Liu N,
Chen J and Wang B: Genistein inhibits growth of human uveal
melanoma cells and affects microRNA-27a and target gene expression.
Oncol Rep. 22:563–567. 2009.PubMed/NCBI
|
|
226
|
Tuaeva NO, Falzone L, Porozov YB, Nosyrev
AE, Trukhan VM, Kovatsi L, Spandidos DA, Drakoulis N, Kalogeraki A,
Mamoulakis C, et al: Translational Application of Circulating DNA
in Oncology: Review of the Last Decades Achievements. Cells.
8:12512019. View Article : Google Scholar :
|
|
227
|
Falzone L, Musso N, Gattuso G, Bongiorno
D, Palermo CI, Scalia G, Libra M and Stefani S: Sensitivity
assessment of droplet digital PCR for SARS-CoV-2 detection. Int J
Mol Med. 46:957–964. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Falzone L, Gattuso G, Lombardo C, Lupo G,
Grillo CM, Spandidos DA, Libra M and Salmeri M: Droplet digital PCR
for the detection and monitoring of Legionella pneumophila. Int J
Mol Med. 46:1777–1782. 2020.PubMed/NCBI
|
|
229
|
Salemi R, Falzone L, Madonna G, Polesel J,
Cinà D, Mallardo D, Ascierto PA, Libra M and Candido S: MMP-9 as a
candidate marker of response to BRAF inhibitors in melanoma
patients with BRAFV600E mutation detected in
circulating-free DNA. Front Pharmacol. 9:8562018. View Article : Google Scholar
|
